Company Overview
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical entity focused on discovering and developing oncology medicines for patients whose tumors are predicted to be sensitive to specific treatments via its generative phosphoproteomics platform. The company functions within the healthcare sector, specifically inside the biotechnology industry, a classification that denotes a focus on the research and development of biological agents rather than manufactured goods. Currently, the enterprise employs 74 individuals and holds a market capitalization of $51.53M, while reporting no annual revenue figures available for the trailing twelve months. These valuation metrics indicate that the company is a small-cap entity with limited current sales traction, positioning it as a high-risk, high-potential venture that relies heavily on successful clinical development to generate future cash flows rather than current profitability.
Financial Health
The company reports a net income of $-77,905,000 for the trailing twelve months, with an EBITDA of $-82,758,000, while revenue data is not available for the current period. The substantial gap between the reported net income loss and the EBITDA figure, alongside the absence of revenue, reveals a cost structure dominated by high operating expenses typical of early-stage biotechnology firms engaged in intensive research and development activities. Free cash flow stands at $-39,543,248, indicating that the company is currently burning cash and lacks the immediate financial flexibility to fund operations without external capital raises or other financing events. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which reflects the standard accounting presentation for companies that have not yet achieved commercial revenue or have not generated sufficient sales to cover their direct costs and overheads in a profitable manner. In terms of balance sheet strength, the company holds $118.58M in cash against a total debt load of $2.71M, resulting in a debt-to-equity ratio of 2.41. Despite the elevated debt-to-equity figure, the significant cash reserve suggests the balance sheet is effectively conservative regarding liquidity risk, as the cash on hand far exceeds the debt obligations. The current ratio is listed at 7.69, a metric that indicates robust short-term liquidity and an ability to cover current liabilities with current assets, though this high ratio often results from the accumulation of cash reserves common in pre-revenue biotech models. Return on Equity is -53.9% and Return on Assets is -32.2%, metrics that reveal management is currently utilizing shareholder capital and assets to generate losses rather than returns, a condition expected for clinical-stage companies but one that signals no immediate economic value creation from invested capital.
Valuation Assessment
The trailing P/E ratio is listed as N/A due to the lack of earnings, while the forward P/E is reported at -0.77, implying that the market is pricing in future earnings recovery or that valuation models are relying on alternative inputs given the negative expected earnings trajectory. The price-to-book ratio is 0.37, indicating that the market values the company at less than one-third of its book value, which suggests a deep discount relative to the assets recorded on the balance sheet rather than a premium. Alternative valuation metrics such as the price-to-sales ratio are N/A due to the absence of revenue data, and the EV/EBITDA stands at 0.78, a low multiple that often characterizes distressed or early-stage assets with high growth potential but currently negative earnings power. The stock has traded between a 52-week low of $1.05 and a 52-week high of $5.65, and without the current share price explicitly provided in the source data, the precise percentage distance from the high or low cannot be calculated, though the wide range demonstrates significant intraperiod volatility. The beta value is 1.80, meaning the stock price exhibits high volatility and is expected to fluctuate with greater intensity than the broader market, reflecting the speculative nature of clinical-stage biopharmaceutical equities.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, as the company has not yet generated consistent revenue streams to calculate growth rates or demonstrate an expanding earnings base. Because the company is a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute income to shareholders but instead retains all earnings to reinvest into its drug discovery platform and clinical trials. This reinvestment strategy is characteristic of clinical-stage biopharmaceutical firms that prioritize expanding their pipeline and securing regulatory approvals over providing current income to investors. The overall growth and income profile is defined by a complete reliance on capital appreciation potential rather than dividend income or historical earnings growth, as the business remains in the developmental phase of its oncology medicine portfolio.